Literature DB >> 30196281

Inhibition of the Notch Signaling Pathway Reduces the Differentiation of Hepatic Progenitor Cells into Cholangiocytes in Biliary Atresia.

Yongzhong Mao, Shaotao Tang, Li Yang, Kang Li.   

Abstract

BACKGROUND/AIMS: Viral infections, especially with rotavirus, are often considered an initiator of the pathogenesis of biliary atresia (BA). However, the mechanism by which rotavirus induces BA is still unclear.
METHODS: A BA mouse model was induced in newborn mice by i.p. inoculation with rhesus rotavirus within 6 h of birth. The expression of Notch pathway-associated molecules (JAG1, JAG2, Notch1, Notch2, Notch3, Notch4, DII1, DII3, and DII4) was measured by quantitative PCR and western blot analysis. Bile duct obstruction was detected by hematoxylin and eosin staining and CK-19 immunohistochemical staining. DAPT was used to inhibit the Notch pathway in vivo and in vitro.
RESULTS: In the livers of patients with BA and rotavirus-induced BA mice, the expression of JAG1 and Notch2 was significantly increased. Inhibition of the Notch pathway by DAPT in vivo ameliorated bile duct obstruction and delayed BA-induced mortality. The serum levels of inflammation cytokines (TNF-α, IL-2, IL-8, and IL-18) were reduced by inhibiting the Notch pathway. The expression of CK19, Sox9, and EpCAM was significantly increased in BA liver, while DAPT treatment decreased the expression of CK19, Sox9, and EpCAM.
CONCLUSION: Notch activation is involved in the pathogenesis of BA by promoting the differentiation of hepatic progenitor cells into cholangiocytes.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Biliary atresia; Cholangiocyte differentiation; Hepatic progenitor cells; Notch pathway

Mesh:

Substances:

Year:  2018        PMID: 30196281     DOI: 10.1159/000493290

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  7 in total

Review 1.  Preclinical insights into cholangiopathies: disease modeling and emerging therapeutic targets.

Authors:  Keisaku Sato; Shannon Glaser; Lindsey Kennedy; Suthat Liangpunsakul; Fanyin Meng; Heather Francis; Gianfranco Alpini
Journal:  Expert Opin Ther Targets       Date:  2019-04-22       Impact factor: 6.902

Review 2.  Biliary Atresia: A Complex Hepatobiliary Disease with Variable Gene Involvement, Diagnostic Procedures, and Prognosis.

Authors:  Consolato M Sergi; Susan Gilmour
Journal:  Diagnostics (Basel)       Date:  2022-01-27

Review 3.  Molecular pathways of liver regeneration: A comprehensive review.

Authors:  Yana V Kiseleva; Sevak Z Antonyan; Tatyana S Zharikova; Kirill A Tupikin; Dmitry V Kalinin; Yuri O Zharikov
Journal:  World J Hepatol       Date:  2021-03-27

4.  Hepatic progenitor cells promote the repair of schistosomiasis liver injury by inhibiting IL-33 secretion in mice.

Authors:  Beibei Zhang; Xiaoying Wu; Jing Li; An Ning; Bo Zhang; Jiahua Liu; Langui Song; Chao Yan; Xi Sun; Kuiyang Zheng; Zhongdao Wu
Journal:  Stem Cell Res Ther       Date:  2021-10-21       Impact factor: 6.832

5.  Re-evaluation of Laparoscopic Hepatic Subcapsular Spider-Like Telangiectasis Sign: A Highly Accurate Method to Diagnose Biliary Atresia in Infants.

Authors:  Yibo Li; Liying Rong; Jingfeng Tang; Huizhong Niu; Zhu Jin; Yun Zhou; Guoqing Cao; Xi Zhang; Shuiqing Chi; Shaotao Tang
Journal:  Front Pediatr       Date:  2022-04-25       Impact factor: 3.418

6.  Identification of signature of gene expression in biliary atresia using weighted gene co-expression network analysis.

Authors:  Yongliang Wang; Hongtao Yuan; Maojun Zhao; Li Fang
Journal:  Medicine (Baltimore)       Date:  2022-09-16       Impact factor: 1.817

7.  Screening identifies small molecules that enhance the maturation of human pluripotent stem cell-derived myotubes.

Authors:  Sridhar Selvaraj; Ricardo Mondragon-Gonzalez; Bin Xu; Alessandro Magli; Hyunkee Kim; Jeanne Lainé; James Kiley; Holly Mckee; Fabrizio Rinaldi; Joy Aho; Nacira Tabti; Wei Shen; Rita Cr Perlingeiro
Journal:  Elife       Date:  2019-11-11       Impact factor: 8.140

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.